Data on prolonged extracorporeal membrane oxygenation (ECMO) usage in influenza associated acute respiratory distress syndrome (ARDS) are lacking. Furthermore, no consensus exists on when to terminate ECMO treatment in refractory cases. This report highlights additional treatment measures and complications in prolonged ECMO therapy and discusses associated ethical burdens.
Case report
We report on a 64-year-old man with confirmed H1N1 influenza virus infection who was successfully weaned from 65-day ECMO treatment with an excellent outcome.
Conclusions
Our experience suggests that prolonged ECMO therapy may be provided as long as only 1-organ failure exists and no lung fibrosis occurs. Active physical therapy, facilitated by ECMO treatment, is crucial and should be performed as early as possible.
ZangrilloA., Biondi-ZoccaiG., LandoniG.Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO.Crit Care.2013; 17(1): R30.
OtterspoorL.C., SmitF.H., van LaarT.J., KeseciogluJ., van DijkD.. Prolonged use of extracorporeal membrane oxygenation combined with prone positioning in patients with acute respiratory distress syndrome and invasive Aspergillosis.Perfusion.2012; 27(4): 335–337.
5.
PeekG.J., MugfordM., TiruvoipatiR.CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial.Lancet.2009; 374(9698): 1351–1363.
6.
BroganT.V., ThiagarajanR.R., RycusP.T., BartlettR.H., BrattonS.L.. Extracorporeal membrane oxygenation in adults with severe respiratory failure: a multi-center database.Intensive Care Med.2009; 35(12): 2105–2114.
7.
LindskovC., JensenR.H., SprogoeP.Extracorporeal membrane oxygenation in adult patients with severe acute respiratory failure.Acta Anaesthesiol Scand.2013; 57(3): 303–311.
8.
MoonS.M., LeeH., MoonJ.H.Prolonged Maintenance of VV ECMO for 104 days with Native Lung Recovery in Acute Respiratory Failure: A Case Report.ASAIO J. 201; 62(2): 315–e17.
9.
WiktorA.J., HaftJ.W., BartlettR.H., ParkP.K., RaghavendranK., NapolitanoL.M.. Prolonged VV ECMO (265 Days) for ARDS without technical complications.ASAIO J.2015; 61(2): 205–206.
10.
NeedhamD.M.. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function.JAMA.2008; 300(14): 1685–1690.
11.
AbramsD., JavidfarJ., FarrandE.Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study.Crit Care.2014; 18(1): R38.
12.
SchmidtM., ZogheibE., RozéH.. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome.Intensive Care Med.2013; 39(10): 1704–1713.
13.
SchmidtM., BaileyM., SheldrakeJ.Predicting survival after extracorporeal membrane oxygenation for severe acute respiratory failure. The Respiratory Extracorporeal Membrane Oxygenation Survival Prediction (RESP) score.Am J Respir Crit Care Med.2014; 189(11): 1374–1382.
14.
EngerT., PhilippA., VidemV.Prediction of mortality in adult patients with severe acute lung failure receiving venovenous extracorporeal membrane oxygenation: a prospective observational study.Crit Care.2014; 18(2): R67.
15.
BeinT., Weber-CarstensS., HerridgeM.. Extracorporeal life support, ethics, and questions at the bedside: how does the end of the pathway look?Intensive Care Med.2015; 41(9): 1714–1715.
16.
CoudroyR., JametA., PenuelasO., ThilleA.W.. Use of Type III procollagen measurement as predictor of lung fibroproliferation in ARDS: early measurement for earlier antifibroproliferative therapy?Intensive Care Med.2015; 41(6): 1159–1160.
17.
DonatiS.Y., PapazianL.. Role of open-lung biopsy in acute respiratory distress syndrome.Curr Opin Crit Care.2008; 14(1): 75–79.
